150 related articles for article (PubMed ID: 30631150)
1. Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers.
Louault K; Bonneaud TL; Séveno C; Gomez-Bougie P; Nguyen F; Gautier F; Bourgeois N; Loussouarn D; Kerdraon O; Barillé-Nion S; Jézéquel P; Campone M; Amiot M; Juin PP; Souazé F
Oncogene; 2019 Apr; 38(17):3261-3273. PubMed ID: 30631150
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.
Williams MM; Lee L; Werfel T; Joly MMM; Hicks DJ; Rahman B; Elion D; McKernan C; Sanchez V; Estrada MV; Massarweh S; Elledge R; Duvall C; Cook RS
Cell Death Dis; 2018 Jan; 9(2):21. PubMed ID: 29343814
[TBL] [Abstract][Full Text] [Related]
3. MCL-1 is a clinically targetable vulnerability in breast cancer.
Winder ML; Campbell KJ
Cell Cycle; 2022 Jul; 21(14):1439-1455. PubMed ID: 35349392
[TBL] [Abstract][Full Text] [Related]
4. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG
Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124
[TBL] [Abstract][Full Text] [Related]
5. CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.
Mitra P; Yang RM; Sutton J; Ramsay RG; Gonda TJ
Oncotarget; 2016 Feb; 7(8):9069-83. PubMed ID: 26812885
[TBL] [Abstract][Full Text] [Related]
6. Targeting of MCL-1 in breast cancer-associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties.
Bonneaud TL; Lefebvre CC; Nocquet L; Basseville A; Roul J; Weber H; Campone M; Juin PP; Souazé F
Cell Death Dis; 2022 Sep; 13(9):787. PubMed ID: 36104324
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?
Williams MM; Cook RS
Oncotarget; 2015 Feb; 6(6):3519-30. PubMed ID: 25784482
[TBL] [Abstract][Full Text] [Related]
8. The Interaction Between Cancer-associated Fibroblasts and Cancer Cells Enhances Bcl-xL and Mcl-1 in Colorectal Cancer.
Maeda A; Takahashi H; Harata S; Watanabe K; Yanagita T; Suzuki T; Ushigome H; Nakai N; Maeda Y; Hirokawa T; Shiga K; Ogawa R; Hara M; Matsuo Y; Mitsui A; Kimura M; Takiguchi S
Anticancer Res; 2022 Mar; 42(3):1277-1288. PubMed ID: 35220217
[TBL] [Abstract][Full Text] [Related]
9. IL-15 regulates Bcl-2 family members Bim and Mcl-1 through JAK/STAT and PI3K/AKT pathways in T cells.
Shenoy AR; Kirschnek S; Häcker G
Eur J Immunol; 2014 Aug; 44(8):2500-7. PubMed ID: 24825007
[TBL] [Abstract][Full Text] [Related]
10. MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors.
Hiraki M; Suzuki Y; Alam M; Hinohara K; Hasegawa M; Jin C; Kharbanda S; Kufe D
Sci Rep; 2016 May; 6():26643. PubMed ID: 27217294
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer.
Hu Y; Dragowska WH; Wallis A; Duronio V; Mayer L
Breast Cancer Res Treat; 2001 Nov; 70(1):11-20. PubMed ID: 11767000
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis.
Harnett CC; Abusneina A; Clément J; Gauthier ER
Cell Biochem Funct; 2015 Jul; 33(5):334-40. PubMed ID: 26178811
[TBL] [Abstract][Full Text] [Related]
13. Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers.
Modugno M; Banfi P; Gasparri F; Borzilleri R; Carter P; Cornelius L; Gottardis M; Lee V; Mapelli C; Naglich JG; Tebben A; Vite G; Pastori W; Albanese C; Corti E; Ballinari D; Galvani A
Exp Cell Res; 2015 Mar; 332(2):267-77. PubMed ID: 25486070
[TBL] [Abstract][Full Text] [Related]
14. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
[TBL] [Abstract][Full Text] [Related]
15. Reduced association of anti-apoptotic protein Mcl-1 with E3 ligase Mule increases the stability of Mcl-1 in breast cancer cells.
Pervin S; Tran A; Tran L; Urman R; Braga M; Chaudhuri G; Singh R
Br J Cancer; 2011 Jul; 105(3):428-37. PubMed ID: 21730980
[TBL] [Abstract][Full Text] [Related]
16. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
17. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Thrane S; Pedersen AM; Thomsen MB; Kirkegaard T; Rasmussen BB; Duun-Henriksen AK; Lænkholm AV; Bak M; Lykkesfeldt AE; Yde CW
Oncogene; 2015 Aug; 34(32):4199-210. PubMed ID: 25362855
[TBL] [Abstract][Full Text] [Related]
18. In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis.
Rochaix P; Krajewski S; Reed JC; Bonnet F; Voigt JJ; Brousset P
J Pathol; 1999 Mar; 187(4):410-5. PubMed ID: 10398099
[TBL] [Abstract][Full Text] [Related]
19. MCL-1 is a master regulator of cancer dependency on fatty acid oxidation.
Prew MS; Adhikary U; Choi DW; Portero EP; Paulo JA; Gowda P; Budhraja A; Opferman JT; Gygi SP; Danial NN; Walensky LD
Cell Rep; 2022 Oct; 41(1):111445. PubMed ID: 36198266
[TBL] [Abstract][Full Text] [Related]
20. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells.
Gomez-Bougie P; Bataille R; Amiot M
Eur J Immunol; 2004 Nov; 34(11):3156-64. PubMed ID: 15459900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
